Hemogenyx Pharmaceuticals Plc
OTC: HOPHF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vladislav Sandler
- Employees
- 16
- Headquarters
- London, United Kingdom
- IPO year
- 2021
- Market cap
- $15.8M
- Website
- https://www.hemogenyx.com
Loading HOPHF…
Loading profile data…Frequently asked questions about HOPHF
What does Hemogenyx Pharmaceuticals Plc (HOPHF) do?
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a...
Where does HOPHF trade?
Hemogenyx Pharmaceuticals Plc (HOPHF) trades on the Other OTC.
What sector is HOPHF in?
Hemogenyx Pharmaceuticals Plc (HOPHF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hemogenyx Pharmaceuticals Plc?
Vladislav Sandler is the chief executive officer of Hemogenyx Pharmaceuticals Plc (HOPHF).
Where is Hemogenyx Pharmaceuticals Plc headquartered?
Hemogenyx Pharmaceuticals Plc is headquartered in United Kingdom.
Does HOPHF pay a dividend?
Hemogenyx Pharmaceuticals Plc (HOPHF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HOPHF go public?
Hemogenyx Pharmaceuticals Plc (HOPHF) completed its initial public offering in 2021.